Abstract
Introduction Methamphetamine is a highly addictive psychostimulant and controlled substance that has detrimental health consequences for chronic users. Amphetamine is a structurally-related stimulant commonly used to treat ADHD, however, it also has a high risk for substance misuse. The objectives of this report were to characterize the regional differences in prescription methamphetamine and amphetamine distribution in the US, and examine potential reasons for variations in distribution.
Methods Data for prescription methamphetamine and amphetamine distribution was obtained from the US Drug Enforcement Administration’s Automation of Reports and Consolidated Orders System (ARCOS) Retail Drug Summary Report for 2019. Quarterly, state, and regional differences in distributions of the two controlled substances were analyzed and.
Results The preponderance (97%) of retail drug distribution for both drugs in 2019 were made through pharmacies. In the same year, prescription methamphetamine (+6.8%) and amphetamine (+5.8%) saw increases in drug distribution from Quarter 1 to Quarter 4.. Across the entire US, total per capita drug weight distribution of amphetamine was exactly 4,000 times higher than methamphetamine. Regionally, total per capita drug weight for methamphetamine was highest in the West (32.2% of total distribution) and lowest in the Northeast (17.4%). The total per capita drug weight for amphetamine was highest in the South (37.0% of total distribution) and lowest in the Northeast (19.4%). The ratio between the 90th and 10th percentiles of per capita drug weight by state was 4.39 for methamphetamine and 2.45 for amphetamine. Distribution of methamphetamine only measured 16.1% of its production quota, while distribution of amphetamine measured 54.0% of its production quota.
Discussion Overall, prescription amphetamine distribution was common while prescription methamphetamine distribution was rare. Regional disparities were also present with lowest distribution of both substances in the Northeast region. The patterns observed in distribution are likely the result of stigmatization, differences in accessibility, and the efforts of initiatives such as the Montana Meth Project. This cycle will likely also change in response to physician recommendation and public opinions surrounding issues for pharmacotherapies for ADHD management.
Competing Interest Statement
Brian J. Piper, PhD was part of an osteoarthritis research team from 2019 to 2021 supported by Pfizer and Eli Lilly. The other authors have no conflicts of interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Sarah Lopera slopera{at}som.geisinger.edu
Victoria O’Kane: vokane{at}som.geisinger.edu
Jessica Goldhirsh: jgoldhirsh{at}som.geisinger.edu
Brian Piper: bpiper{at}som.geisinger.edu
Disclosures: BJP was part of an osteoarthritis research team from 2019 to 2021 supported by Pfizer and Eli Lilly. The other authors have no conflicts of interest.
Data Availability
Publicly available datasets were analyzed in this study. All data produced are available online at
https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2019.pdf
https://deadiversion.usdoj.gov/fed_regs/quotas/2018/fr1228.htm
